[Congressional Bills 114th Congress]
[From the U.S. Government Publishing Office]
[S. 2512 Referred in House (RFH)]

<DOC>






114th CONGRESS
  2d Session
                                S. 2512


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             March 21, 2016

            Referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 AN ACT


 
To expand the tropical disease product priority review voucher program 
                to encourage treatments for Zika virus.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Adding Zika Virus to the FDA 
Priority Review Voucher Program Act''.

SEC. 2. EXPANDING TROPICAL DISEASE PRODUCT PRIORITY REVIEW VOUCHER 
              PROGRAM TO ENCOURAGE TREATMENTS FOR ZIKA VIRUS DISEASE.

    Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 360n(a)(3)) is amended--
            (1) by redesignating subparagraph (R) as subparagraph (S);
            (2) in subparagraph (Q), by striking ``Filoviruses'' and 
        inserting ``Filovirus Diseases''; and
            (3) by inserting after subparagraph (Q) the following:
                    ``(R) Zika Virus Disease.''.

            Passed the Senate March 17, 2016.

            Attest:

                                                JULIE E. ADAMS,

                                                             Secretary.
